drugset / Trial / NCT02524717
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the pharmacokinetics of JNJ-56021927 in participants with mild and moderate hepatic impairment.
Timeline
- Start
- 2015-08-13
- Primary completion
- 2017-02-09
- Completion
- 2017-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | 240 mg | Oral |
Indications
No indication recorded.